Policy & Advocacy

Biden-Harris Administration Announces New CGT Payment Model

Margarita Valdez Martínez | February 01, 2024

On Tuesday, January 30, the Biden-Harris Administration announced the cell and gene therapy (CGT) access model. This model will enable the Centers for Medicare and Medicaid Services (CMS) to negotiate outcomes-based agreements with manufacturers. The CGT model is expected to launch in January 2025, and enrollment for states and select territories will be on a rolling basis. This multi-year model will be voluntary for both states and manufacturers. 

Policy & Advocacy
Read Full Story

Looking Back at 2023's Policy and Advocacy Highlights

Margarita Valdez Martínez | January 18, 2024

Learn about last year's successes and highlights from ASGCT's Policy and Advocacy team.

Policy & Advocacy
Read Full Story

Apply for the Congressional Policy Fellowship to Share Your CGT Expertise with Policymakers

Apply through Jan. 15, 2024 | November 07, 2023

We'll place you in a congressional office where you'll share your CGT knowledge with legislators in Washington, D.C. Apply through Jan. 15, 2024!

Policy & Advocacy
Read Full Story

Medicaid Paper Offers Policy Solutions for Equitable CGT Access 

Rayne Rouce, MD | June 23, 2023

A group of experts published a review that sheds light on the challenges of equitable patient access within the Medicaid system.

Policy & Advocacy
Read Full Story

The Federal Budget Process and Its Impact on Your Research Program

Christina Mayer, MPA | April 04, 2023

ASGCT is a strong supporter of robust funding to federal regulatory and research agencies. Find out how the Congressional budget process has a direct impact on the gene and cell therapy field.

Policy & Advocacy
Read Full Story

Learn How ASGCT Impacted FDA Guidance for CGT

Chiagbanwe (ChiChi) Enwere, MPH | March 14, 2023

FDA acknowledged Society comments in recent guidance documents.

Policy & Advocacy
Read Full Story

ASGCT Members Share Science Behind Immunotherapies with Federal Policymakers

Margarita Valdez Martínez | February 23, 2023

Last month, ASGCT members collaborated with the House Cancer Caucus on a briefing on innovative immunotherapies for cancer treatment to improve patient access. The Society is grateful for the opportunity to better inform regulatory and legislative policymakers about gene and cell therapies. 

Policy & Advocacy
Read Full Story

HHS Secretary Announces CGT Access Model

Margarita Valdez Martínez | February 15, 2023

CMS announces three new payment models for testing by the Center for Medicare and Medicaid Innovation. A proposed Cell and Gene Therapy Access Model has the potential for a far-reaching impact on the CGT field.

Policy & Advocacy
Read Full Story

Looking Back at a Year of Advocacy Progress

Caitlin McCombs, MBA | February 03, 2023

Learn what ASGCT's Policy & Advocacy team accomplished in 2022 and what they're excited about in 2023.

Policy & Advocacy
Read Full Story

Omnibus Spending Package: What It Means for Researchers

Christina Mayer, MPA | December 23, 2022

The omnibus spending package for the 2023 Fiscal Year includes a number of ASGCT-supported provisions that will impact the field of cell and gene therapy. Learn what this means for FDA, NIH, and more. 

Policy & Advocacy
Read Full Story

FDA Approves First CAR T-Cell Therapy for ALL

ASGCT Staff | October 14, 2021

This marks approval of a second disease indication for Tecartus, which received accelerated approval for the treatment of adults with r/r mantle cell lymphoma in July 2020.

Policy & Advocacy
Read Full Story

ASGCT Gears Up for 2021 Policy Progress

Francesca Cook, MPH | January 12, 2021

Read about the Society's policy and advocacy successes of 2020 and our goals for 2021.

Policy & Advocacy
Read Full Story

ASGCT Holds First Joint Meeting With Brazilian Association

ASGCT Staff | December 03, 2020

Speakers addressed the scientific and infrastructural requirements for successful translation into clinical research for oncology, hemophilia, and sickle cell disease.

Policy & Advocacy
Read Full Story

Policy Summit’s Sickle Cell Disease Session Emphasizes Patient Access

Emily Nettesheim | October 05, 2020

The Policy Summit session on sickle cell disease focused on patient education and the policy reforms necessary to bring curative gene therapy treatments to the millions of patients suffering from SCD around the world.

Policy & Advocacy  |  Policy Summit
Read Full Story
2024

Register for the 27th Annual Meeting

May 7-11, 2024 | Baltimore, MD

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.